Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178862 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
A Phase 3 study, sponsored by Scynexis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
NCT05178862 is a Phase 3 study that was terminated before completion, run by Scynexis. The registered enrollment target is 68 participants.
The verdict
NCT05178862, a Phase 3 study, was terminated before completion, sponsored by Scynexis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
Interventions
- DRUG Fluconazole
- DRUG SCY-078
- DRUG Echinocandin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2025-12-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05178862
The ClinicalTrials.gov registry entry for NCT05178862 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluconazole is the first listed.
NCT05178862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05178862 about?
NCT05178862 is a clinical study titled "A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole". This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.
What is the current status of trial NCT05178862?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2022-08-03. Estimated completion is 2025-12-16.
What interventions are being tested in trial NCT05178862?
The interventions under investigation include: Fluconazole (DRUG), SCY-078 (DRUG), Echinocandin (DRUG).
Who is sponsoring clinical trial NCT05178862?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.